Begoña Mellado

Sobre mi

Publicacions destacades

• Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study

  Autors:

  Rodriguez-Vida A; Maroto P; Font A; Martin C; Mellado B;

  (...)

  Taus A; Martinez-Garcia M; Juanpere N; Juan O; Bellmunt J .

  Veure llistat complet d'autors

  Referència: British Journal Of Cancer 2023.

• A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

  Autors:

  Climent, MA; Font, A; Durán, I; Puente, J; Méndez-Vidal, MJ;

  (...)

  Lázaro-Quintela, M; Cassinello-Espinosa, J; Pérez-Valderrama, B; Garcias, C; Castellano, D.

  Veure llistat complet d'autors

  Referència: European Journal Of Cancer 2022.

• Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial

  Autors:

  Nicholas J. Vogelzang; MD; Tomasz M. Beer; MD; Winald Gerritsen;

  (...)

  PhD; and Radek Spisek; MD; PhD ; for the VIABLE Investigators.

  Veure llistat complet d'autors

  Referència: Jama Oncology 2022.

• Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

  Autors:

  Matthew R. Smith; Howard I. Scher; Shahneen Sandhu; Eleni Efstathiou; Primo N. Lara;

  (...)

  Karen A. Urtishak; Peter Francis; Angela Lopez-Gitlitz; and Karim Fizazi; on behalf of the GALAHAD investigators†.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2022.

• Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

  Autors:

  Motzer, RJ; Powles, T; Atkins, MB; Escudier, B; McDermott, DF;

  (...)

  Craine, V; Huseni, M; Flinn, N; Dubey, S; Rini, B.

  Veure llistat complet d'autors

  Referència: Jama Oncology 2022.

• Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

  Autors:

  Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA;

  (...)

  Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y; BLC2001 Study Group.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2022.

• Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

  Autors:

  Powles, T; Yuen, KC; Gillessen, S; Kadel, EE; Rathkopf, D;

  (...)

  Rasuo, G; Datye, A; Mariathasan, S; Williams, P; Sweeney, CJ.

  Veure llistat complet d'autors

  Referència: Nature Medicine 2022.

• Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes

  Autors:

  Marin-Aguilera, M; Pereira, MV; Jimenez, N; Reig, O; Cuartero, A;

  Victoria, I; Aversa, C; Ferrer-Mileo, L; Prat, A; Mellado, B.

  Referència: Cancers 2021.

• Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment

  Autors:

  de Porras, VR; Wang, XC; Palomero, L; Marin-Aguilera, M; Solé-Blanch, C;

  (...)

  Beltran, H; Mellado, B; Martinez-Balibrea, E; Font, A; Aytes, A.

  Veure llistat complet d'autors

  Referència: European Urology 2021.

• Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer

  Autors:

  Marin-Aguilera, Mercedes; Jimenez, Natalia; Reig, Oscar; Montalbo, Ruth; Verma, Ajit K;

  (...)

  Cabezon, Raquel; Gonzalez, Azucena; Juan, Manel; Prat, Aleix; Mellado, Begona.

  Veure llistat complet d'autors

  Referència: Cells 2020.